San Francisco has taken a big step toward becoming the first major US city to require drug makers to fund and administer a citywide take-back program in which consumers can bring unused and unexpired medicines to drop-off destinations for disposal.
San Francisco has taken a big step toward becoming the first major US city to require drug makers to fund and administer a citywide take-back program in which consumers can bring unused and unexpired medicines to drop-off destinations for disposal. An ordinance was approved unanimously last week by the city’s Board of Supervisors and now awaits the signature of Mayor Edwin Lee, who has until Friday to sign the bill or it automatically becomes law.
The bill mimics a groundbreaking law passed 3 years ago by Alameda County, California, to establish a program over the protests of the pharmaceutical industry. Since then, drug makers have been concerned that other local governments will be emboldened to pass similar laws, raising their costs around the country.
Read more at The Wall Street Journal's Pharmalot blog: http://on.wsj.com/1BrZVV5
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More